Tae Il Noh

Dr. Tae Il Noh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Journal of Endourology
Verified
Journal Article
Closed access
TNTae Il Noh
Tae Il Noh
YKYoung Jin Kang
Young Jin Kang
JSJi Sung Shim
Ji Sung Shim
SKSeok Ho Kang
Seok Ho Kang
JCJun Cheon
Jun Cheon
SKSung Gu Kang
Sung Gu Kang
Purpose: To compare the perioperative outcomes of patients who underwent single-port (SP) robot-assisted radical prostatectomy (RARP) and those who underwent multi-port (MP)-RARP. Methods: Data on 40 consecutive patients who underwent SP-RARP between June 2020 and February 2021 and 129 who underwent MP-RARP between June 2019 and February 2021 were retrospectively reviewed. Using logistic regression, 31 patients who underwent SP-RARP were matched to 31 patients who underwent MP-RARP (1:1) based on propensity scores. The available perioperative parameters and outcomes were analyzed. Results: Compared to MP-RARP, SP-RARP showed no significant differences in perioperative parameters, including the console times (111.0±15.7 vs. 102.6±18.8 minutes, p=0.569), operation time (151.3±15.1 vs. 158.7±20.3 minutes, p=0.863), estimated blood loss (121.1±64.7 vs. 140.5±90.5 mL, p=0.638), positive surgical margins (19.4% in both groups), and 3-month continence (77.4% vs. 83.9%, p=0.563) and potency (45.2% vs. 48.4%, p=0.891) rates. Patients who underwent SP-RARP had lower proportions of complete nerve sparing than those who underwent MP-RARP (SP-RARP vs. MP-RARP in subjective scores: 4.0±0.8 vs. 4.4±0.9, p=0.046; SP-RARP vs. MP-RARP in pathologic score of 5, 35.5% vs. 64.5%, p=0.049; score of 4, 41.9% vs. 19.4%, p=0.038; score of 3, 19.4% vs. 9.7%, p=0.398; score of 2, 3.2% vs. 0.0%, p=0.365; and score of 1, 3.2% vs. 3.2%, p=0.932, respectively). Conclusions: SP-RARP showed lower nerve sparing scores than MP-RARP, the present study suggests that SP-RARP is safe and feasible with comparable short-term functional outcomes as those of MP-RARP.

5 January 2022 in Prostate International
Verified
Journal Article
Open access
TNTae Il Noh
Tae Il Noh
JTJong Hyun Tae
Jong Hyun Tae
JSJi Sung Shim
Ji Sung Shim
SKSeok Ho Kang
Seok Ho Kang
JCJun Cheon
Jun Cheon
SKSung Gu Kang
Sung Gu Kang
With the implementation of da Vinci SP robot platform (Intuitive Surgical, Inc., Sunnyvale, CA, USA), we described our initial experience with the da Vinci SP robot platform (Intuitive Surgical, Inc., Sunnyvale, CA, USA) for single-port robotic-assisted radical prostatectomy (SP-RARP). This retrospective review included 30 consecutive patients with prostate biopsy-confirmed prostate cancer who underwent SP-RARP by a single surgeon between June and November 2020. SP-RARP was performed with a single-incision plus one method, in which the multichannel guide port was inserted directly with an additional assist port. We report our initial experience of perioperative and early functional outcomes. The mean operative time (SD), console time (SD), and blood loss were 142.8 (15.1) min, 109.9 (15.7) min, and 133.0 (72.9) mL, respectively. No intraoperative complications or blood transfusions were reported. Of the 30 patients, 21 (70.0%), 7 (23.3%) and 2 (6.7%) had stage pT2, pT3a and pT3b disease, respectively. Positive surgical margins were reported in 5 of the 30 (16.7%) patients in the final pathology report, including 2 of 21 (9.5%) with stage pT2 and 3 of 9 (33.3%) with ≥ pT3. At 12 weeks after SP-RARP, 80.0% of patients had achieved continence and the potency was 46.7%; 8 of 11 (72.7%) had sexual health inventory for men (SHIM) scores ≥ 17 and 6 of 19 (31.6%) had SHIM scores < 17. The SP platform for radical prostatectomy was technically safe and feasible. After overcoming the technical learning curve, this platform may provide high-quality outcomes comparable to those of multi-port platforms.

1 January 2026 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
ALAlvin Christopher Lavadia
Alvin Christopher Lavadia
JKJae Heon Kim
Jae Heon Kim
SYSeong Woo Yun
Seong Woo Yun
TNTae Il Noh
Tae Il Noh
Lavadia AC, et al. World J Mens Health. 2026 Jan;44(1):36-48. https://doi.org/10.5534/wjmh.240237

1 January 2025 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
JKJae Heon Kim
Jae Heon Kim
GBGi Hwan Bae
Gi Hwan Bae
JJJaehun Jung
Jaehun Jung
TNTae Il Noh
Tae Il Noh
Kim JH, et al. World J Mens Health. 2025 Jan;43(1):123-133. https://doi.org/10.5534/wjmh.230237

1 January 2022 in Investigative and Clinical Urology
Verified
Journal Article
Open access
HKHa Eun Kang
Ha Eun Kang
SKSeung Bin Kim
Seung Bin Kim
TNTae Il Noh
Tae Il Noh
JISUNG SHIMJISUNG SHIM
JISUNG SHIM
SKSeok Ho Kang
Seok Ho Kang
SKSung Gu Kang
Sung Gu Kang
Kang HE, et al. Investig Clin Urol. 2022 Oct;63:e80. https://doi.org/10.4111/icu.20220235

1 January 2024 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
CHChang Wan Hyun
Chang Wan Hyun
JHJae Young Hwang
Jae Young Hwang
SYSeong Woo Yun
Seong Woo Yun
TPTae Young Park
Tae Young Park
SYSung Goo Yoon
Sung Goo Yoon
JISUNG SHIMJISUNG SHIM
JISUNG SHIM
Hyun CW, et al. Investig Clin Urol. 2024 Mar;65(2):165-172. https://doi.org/10.4111/icu.20230272